Korvaltab

General characteristics. Structure:

Active ingredients: ethyl ether of α-bromizovalerianovy acid - 8,2 mg; phenobarbital - 7,5 mg; oils mint - 0,58 mg;

Excipients: β-cyclodextrin, potato starch, tabletoz (lactoses monohydrate), cellulose microcrystallic, magnesium stearate.

Pharmacological properties:

Sedative, vasodilating, antispasmodic. Promotes decrease in excitability of the central nervous system, has the calming effect and facilitates approach of a natural dream. The ethyl ether     of α-bromizovalerianovy acid which is a part of drug has sedative and spasmolytic effect, similar to effect of extract of a valerian; in high doses renders also easy somnolent effect. Phenobarbital has sedative and moderate spasmolytic effect. Mint oil renders reflex vasodilating and spasmolytic effect.

Indications to use:

- Neurosises with an acrimony;
- sleeplessness;
- in complex therapy of an idiopathic hypertensia and vegeto-vascular dystonia;
- unsharply expressed spasm of coronary vessels, tachycardia;
- the enterospasms caused by neurovegetative frustration (as spasmolytic drug).

Route of administration and doses:

The dosage and duration of a course of treatment are established by the doctor individually for each patient.
The adult, as a rule, to appoint 1-2 tablets of drug 2-3 times a day to food.
At tachycardia and spasms of coronary vessels it is possible to increase a single dose to 3 tablets.

Children.
Experience of use for treatment of children is absent therefore drug is not used in pediatric practice.

Features of use:

During treatment drug does not recommend to engaged in activity which requires special attention, bystry mental and motor reactions.
During administration of drug it is necessary to avoid the use of alcoholic drinks.
Existence in composition of medicine of phenobarbital can result in risk of emergence of a syndrome of Stephens-Johnson and Layell that most likely in the first weeks of treatment. Prolonged use in view of danger of development of medicamentous dependence, possible accumulation of bromine in an organism and development of poisoning with bromine is not recommended. In cases when pain in heart does not pass after administration of drug, it is necessary to see a doctor for an exception of an acute coronary syndrome. It is necessary to appoint carefully drug at arterial hypotension, hyperkinesias, a hyperthyroidism, a hypoadrenalism, acute and constant Bol, acute intoxication medicines.

Drug contains lactose therefore to patients with hereditary intolerance of lactose galactose Korvaltab is not recommended to apply.

Use during pregnancy or feeding by a breast.
Not to appoint drug pregnant and during feeding a breast.

Ability to influence speed of response at control of motor transport or other mechanisms.
Korvaltab can cause drowsiness and dizziness therefore during treatment patients are not recommended to work with dangerous mechanisms and to manage vehicles.

Side effects:

Korvaltab is, as a rule, had well.
In some cases such side effects can be observed:
from the alimentary system: locks, heavy feeling in epigastric area, at prolonged use - an abnormal liver function, nausea, vomiting;
from a nervous system: weakness, ataxy, incoordination, nystagmus, hallucinations, paradoxical arousing, decrease in concentration of attention, fatigue, block of reactions, headache, cognitive disturbances, confusion of consciousness, drowsiness, slight dizziness;
from the hemopoietic system: anemia, thrombocytopenia, agranulocytosis;
from cardiovascular system: arterial hypotension, bradycardia;  
from immune system: hypersensitivity reactions, including a Quincke's disease, allergic reactions (including skin rash, an itch, a small tortoiseshell);
from skin and mucous covers: Stephens-Johnson's syndrome, toxic epidermal necrolysis;
from a musculoskeletal system: at prolonged use of means which contain phenobarbital there is a risk of disturbance of bone formation.
another: utrudnenny breath.
Long administration of drugs, containing bromine, can lead to poisoning with bromine which is characterized: oppression of the central nervous system, depressive mood, confusion of consciousness, ataxy, apathy, conjunctivitis, rhinitis, dacryagogue, acne or purpura.   
The specified phenomena pass at a dose decline or the termination of administration of drug.

Interaction with other medicines:

During a concomitant use of drug with other medicines which oppress the central nervous system, perhaps mutual strengthening of action. Effect of drug amplifies against the background of use of drugs of valproic acid, alcohol. Phenobarbital induces enzymes of a liver and, respectively, can accelerate metabolism of some medicines which are metabolized by liver enzymes (including indirect anticoagulants, cardiac glycosides, antimicrobic, antiviral, antifungal, antiepileptic, anticonvulsant, psychotropic, peroral sakharponizhayushchy, hormonal, immunosuppressive, cytostatic, antiaritimichesky, anti-hypertensive medicines, etc.)  

Phenobarbital strengthens action of analgetics and mestnoanesteziruyushchy anastetik.

MAO inhibitors prolong effect of phenobarbital. Rifampicin can reduce effect of phenobarbital.

At a concomitant use of phenobarbital with drugs of gold the risk of damage of kidneys increases.

At prolonged simultaneous use of phenobarbital with non-steroidal anti-inflammatory drugs there is a risk of ulceration of a stomach and bleeding. 

Simultaneous use of phenobarbital with a zidovudine increases toxicity of both drugs.

Drug increases toxicity of a methotrexate.

Contraindications:

- Hypersensitivity to drug components;
- the expressed abnormal liver functions and/or kidneys;
- hepatic porphyria;
- heavy heart failure.

The medicines containing phenobarbital are contraindicated at the expressed arterial hypotension, an acute myocardial infarction, a diabetes mellitus, a depression, a myasthenia, alcoholism, drug and medicinal addiction, respiratory diseases with an otdyshka, an obstructive syndrome.

Overdose:

The overdose is possible at frequent or long use of drug that it is connected with cumulation of its components. Prolonged and constant use can result in dependence, an abstinence syndrome, psychomotor excitement.

Overdose symptoms: respiratory depression, up to its stop; oppression of the central nervous system, up to a coma; oppression of cardiovascular activity, including disturbance of a rhythm, a lowering of arterial pressure up to a kolaptoidny state; nausea, weakness, decrease in body temperature, reduction of a diuresis.

Treatment: symptomatic.

Storage conditions:

To store in the place, unavailable to children, in original packaging at a temperature not over 25 ºС.

Issue conditions:

Without recipe

Packaging:

On 10 tablets in the blister; on 2 and 10 blisters in a pack from a cardboard.